Benjamin Pendergrass
Optometrist · Huntsville, ALNPI 1396030912
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Coopervision Inc. at 52.8% of the total. 2025 is the largest year on record at $4,884, 5.5 times the $887 reported in 2019. Among optometrist clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $56.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$5K
- Alcon$1K
- Johnson & Johnson Vision Care, Inc.$753
- Glaukos Corporation$396
- Bausch & Lomb Americas Inc.$381
- Sun Pharmaceutical Industries Inc.$372
- plus $1K from 11 others
What the payments were for
- Consulting fees$3,37536%
- Travel & lodging$6607%
- Food & beverage$5,39557%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 32 | $4,978 |
| Alcon | 26 | $1,130 |
| Johnson & Johnson Vision Care, Inc. | 22 | $753 |
| Glaukos Corporation | 3 | $396 |
| Bausch & Lomb Americas Inc. | 16 | $381 |
| Sun Pharmaceutical Industries Inc. | 18 | $372 |
| Tarsus Pharmaceuticals, Inc. | 9 | $288 |
| AbbVie(2 entities) | 10 | $158 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $137 |
| Astellas Pharma US Inc | 1 | $134 |
| Dompe US, Inc. | 2 | $133 |
| Novartis | 6 | $128 |
| Biotissue Holdings Inc. | 2 | $127 |
| Oyster Point Pharma, Inc. | 6 | $126 |
| Sight Sciences, Inc. | 3 | $106 |
| Aerie Pharmaceuticals, Inc. | 3 | $45 |
| Shire North American Group Inc | 3 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MiSight Contact Lens$4,086
- Acuvue$370
- Precision 1$340
- KXL System$269
- TOTAL30$263
- XDEMVY$125
- Clariti Contact Lens$125
- MIEBO$120
- Photrexa$119
- DAILIES TOTAL1$114
- MyDay Contact Lens$110
- Oxervate$110
- Multiple Brands Contact Lens$109
- Prokera$102
- AmnioGraft$102
How this compares
$9,435 in reported general payments places this provider in the 95th percentile of 749 optometrist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 57 | $77,511 |
| LumiganBimatoprost | 94 | $36,960 |
| XdemvyLotilaner | 18 | $33,503 |
| Cyclosporine | 17 | $13,727 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 36 | $6,171 |
| Latanoprost | 264 | $4,522 |
| Timolol Maleate | 120 | $3,061 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $2,584 |
| Travoprost | 15 | $1,763 |
| Brimonidine Tartrate | 47 | $1,698 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 74 | $1,527 |
| Prednisolone Acetate | 19 | $839 |
| ErythromycinErythromycin Base | 38 | $488 |
| Dorzolamide Hcl | 30 | $362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $158 | $114,470151 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $288 | $33,50318 claims |
| AlconSimbrinza | $1,130 | $2,58413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 749 optometrist providers in Alabama.
Other optometrist in Huntsville
- Neena JamesHuntsville$74K
- Tracey Schroeder SwartzHuntsville$69K
- Patricia FulmerHuntsville$45K
- Mohammed HaqueHuntsville$10K
- Kristin SullinsHuntsville$7K
- Jessica BoydHuntsville$6K
- Alan PeasleeHuntsville$6K
- Kenneth MoultrieHuntsville$5K
- Mark SchaefferHoover$470K
- Kelly NicholsBirmingham$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.